Victrelis

Victrelis is a brand name of boceprevir, approved by the FDA in the following formulation(s):

VICTRELIS (boceprevir - capsule; oral)

• 
  Manufacturer: SCHERING
  
  Approval date: May 13, 2011
  
  Strength(s): 200MG ^[RLD]

Has a generic version of Victrelis been approved?

No. There is currently no therapeutically equivalent version of Victrelis available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Victrelis. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Peptides as NS3-serine protease inhibitors of hepatitis C virus
  Patent 7,012,066
  Issued: March 14, 2006
  Inventor(s): Saksena; Anil K. & Girijavallabhan; Viyyoor Moopil & Lovey; Raymond G. & Jao; Edwin & Bennett; Frank & Mc Cormick; Jinping L. & Wang; Haiyan & Pike; Russell E. & Bogen; Stephane L. & Chan; Tin-Yau & Liu; Yi-Tsung & Zhu; Zhaoning & Njoroge; F. George & Arasappan; Ashok & Parekh; Teja
  Assignee(s): Schering Corporation
  Dendreon Corporation
  The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
  
  Patent expiration dates:
  
  
  • February 22, 2022
    
    ✓ 
    Patent use: TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN IN ADULT PATIENTS (>=18 YEARS OF AGE) WITH COMPENSATED LIVER DISEASE
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Pharmaceutical formulations and methods of treatment using the same
  Patent 7,772,178
  Issued: August 10, 2010
  Inventor(s): Malcolm; Bruce A. & Bradley; Prudence K. & Pavlovsky; Anastasia & Cho; Wing-Kee Philip & Qiu; Zhihui
  Assignee(s): Schering Corporation
  Pharmaceutical formulations containing at least one compound of Formulae I-XXVI herein and at least one surfactant. Pharmaceutically acceptable carriers and excipients may also be included in the formulations. The formulations of the present invention are suited for use in single unit dosages.
  
  Patent expiration dates:
  
  
  • November 11, 2027
    
    ✓ 
    Patent use: TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN IN ADULT PATIENTS (>=18 YEARS OF AGE) WITH COMPENSATED LIVER DISEASE
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • May 13, 2016 - NEW CHEMICAL ENTITY
  
  

See also...

• Victrelis Consumer Information (Drugs.com)
• Victrelis Consumer Information (Wolters Kluwer)
• Victrelis Consumer Information (Cerner Multum)
• Boceprevir Consumer Information (Wolters Kluwer)
• Boceprevir Consumer Information (Cerner Multum)